OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 275,291 shares, a decline of 36.8% from the February 26th total of 435,430 shares. Based on an average daily volume of 116,655 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. B. Riley Financial initiated coverage on OKYO Pharma in a research note on Monday, December 8th. They set a “buy” rating and a $5.00 price target on the stock. Piper Sandler initiated coverage on OKYO Pharma in a report on Friday, February 20th. They issued an “overweight” rating and a $7.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, OKYO Pharma presently has an average rating of “Hold” and an average target price of $6.33.

Institutional Investors Weigh In On OKYO Pharma

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of OKYO Pharma in the 4th quarter valued at approximately $36,000. Renaissance Technologies LLC lifted its position in shares of OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in OKYO Pharma in the 3rd quarter valued at $31,000. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Price Performance

Shares of OKYO Pharma stock opened at $1.58 on Friday. OKYO Pharma has a 52-week low of $1.03 and a 52-week high of $3.35. The company’s fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.08.

OKYO Pharma (NASDAQ:OKYO) last released its quarterly earnings data on Friday, January 30th. The company reported ($2.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($2.21). As a group, research analysts anticipate that OKYO Pharma will post -0.17 EPS for the current year.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.